# OSI Systems Inc: financial statements, quarterly

OSIS · Nasdaq · CIK 1039065 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/osis.md) · [Financials](/companies/osis/financials.md) · [Filings](/companies/osis/filings.md) · [Insiders](/companies/osis/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/osis/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [373](/filings/0001410578-25-001887.md) | [405](/filings/0001410578-25-001887.md) | [481](/filings/0001410578-25-001887.md) | [344](/filings/0001104659-26-099752.md) | [420](/filings/0001104659-26-099752.md) | [444](/filings/0001104659-26-099752.md) | [505](/filings/0001104659-26-099752.md) | [385](/filings/0001104659-26-120281.md) | [464](/filings/0001104659-26-099752.md) | [453](/filings/0001104659-26-099752.md) | [484](/filings/0001104659-26-099752.md) | [403](/filings/0001104659-26-120281.md) |
| Cost of revenue | $m | [232](/filings/0001410578-25-001887.md) | [269](/filings/0001410578-25-001887.md) | [327](/filings/0001410578-25-001887.md) | [223](/filings/0001104659-26-099752.md) | [273](/filings/0001104659-26-099752.md) | [294](/filings/0001104659-26-099752.md) | [337](/filings/0001104659-26-099752.md) | [261](/filings/0001104659-26-120281.md) | [312](/filings/0001104659-26-099752.md) | [303](/filings/0001104659-26-099752.md) | [316](/filings/0001104659-26-099752.md) | [280](/filings/0001104659-26-120281.md) |
| Gross profit | $m | [141](/filings/0001410578-25-001887.md) | [136](/filings/0001410578-25-001887.md) | [154](/filings/0001410578-25-001887.md) | [122](/filings/0001104659-26-099752.md) | [147](/filings/0001104659-26-099752.md) | [150](/filings/0001104659-26-099752.md) | [168](/filings/0001104659-26-099752.md) | [123](/filings/0001104659-26-120281.md) | [152](/filings/0001104659-26-099752.md) | [150](/filings/0001104659-26-099752.md) | [168](/filings/0001104659-26-099752.md) | [124](/filings/0001104659-26-120281.md) |
| Research and development | $m | [16.4](/filings/0001410578-25-001887.md) | [17.1](/filings/0001410578-25-001887.md) | [15.9](/filings/0001410578-25-001887.md) | [17.8](/filings/0001104659-26-099752.md) | [18.3](/filings/0001104659-26-099752.md) | [18.6](/filings/0001104659-26-099752.md) | [18.8](/filings/0001104659-26-099752.md) | [20.4](/filings/0001104659-26-120281.md) | [19.8](/filings/0001104659-26-099752.md) | [19.5](/filings/0001104659-26-099752.md) | [19.5](/filings/0001104659-26-099752.md) | [19.4](/filings/0001104659-26-120281.md) |
| Selling, general and administrative | $m | [71.6](/filings/0001410578-25-001887.md) | [66.6](/filings/0001410578-25-001887.md) | [71.7](/filings/0001410578-25-001887.md) | [72.2](/filings/0001104659-26-099752.md) | [70.7](/filings/0001104659-26-099752.md) | [73.2](/filings/0001104659-26-099752.md) | [74.7](/filings/0001104659-26-099752.md) | [67.0](/filings/0001104659-26-120281.md) | [70.2](/filings/0001104659-26-099752.md) | [71.5](/filings/0001104659-26-099752.md) | [69.7](/filings/0001104659-26-099752.md) | [68.7](/filings/0001104659-26-120281.md) |
| Operating income | $m | [52.3](/filings/0001410578-25-001887.md) | [51.4](/filings/0001410578-25-001887.md) | [62.8](/filings/0001410578-25-001887.md) | [30.3](/filings/0001104659-26-099752.md) | [58.0](/filings/0001104659-26-099752.md) | [56.2](/filings/0001104659-26-099752.md) | [73.0](/filings/0001104659-26-099752.md) | [33.1](/filings/0001104659-26-120281.md) | [58.8](/filings/0001104659-26-099752.md) | [53.2](/filings/0001104659-26-099752.md) | [73.9](/filings/0001104659-26-099752.md) | [33.6](/filings/0001104659-26-120281.md) |
| Interest expense | $m | [6.5](/filings/0001410578-25-001887.md) | [7.4](/filings/0001410578-25-001887.md) | [8.2](/filings/0001410578-25-001887.md) | [7.4](/filings/0001104659-26-099752.md) | [8.6](/filings/0001104659-26-099752.md) | [8.2](/filings/0001104659-26-099752.md) | [7.2](/filings/0001104659-26-099752.md) | [7.4](/filings/0001104659-26-120281.md) | [10.7](/filings/0001104659-26-099752.md) | [4.0](/filings/0001104659-26-099752.md) | [4.1](/filings/0001104659-26-099752.md) | [3.3](/filings/0001104659-26-120281.md) |
| Income tax | $m | [9.2](/filings/0001410578-25-001887.md) | [9.9](/filings/0001410578-25-001887.md) | [10.0](/filings/0001410578-25-001887.md) | [5.0](/filings/0001104659-26-099752.md) | [11.5](/filings/0001104659-26-099752.md) | [6.9](/filings/0001104659-26-099752.md) | [13.1](/filings/0001104659-26-099752.md) | [5.1](/filings/0001104659-26-120281.md) | [9.4](/filings/0001104659-26-099752.md) | [9.0](/filings/0001104659-26-099752.md) | [14.5](/filings/0001104659-26-099752.md) | [5.7](/filings/0001104659-26-120281.md) |
| Net income | $m | [36.6](/filings/0001410578-25-001887.md) | [34.0](/filings/0001410578-25-001887.md) | [44.7](/filings/0001410578-25-001887.md) | [17.9](/filings/0001104659-26-099752.md) | [37.8](/filings/0001104659-26-099752.md) | [41.1](/filings/0001104659-26-099752.md) | [52.7](/filings/0001104659-26-099752.md) | [20.6](/filings/0001104659-26-120281.md) | [38.7](/filings/0001104659-26-099752.md) | [40.2](/filings/0001104659-26-099752.md) | [55.2](/filings/0001104659-26-099752.md) | [24.6](/filings/0001104659-26-120281.md) |
| Diluted EPS | $ per share | [2.11](/filings/0001410578-25-001887.md) | [1.95](/filings/0001410578-25-001887.md) | [2.55](/filings/0001410578-25-001887.md) | [1.05](/filings/0001104659-26-099752.md) | [2.22](/filings/0001104659-26-099752.md) | [2.40](/filings/0001104659-26-099752.md) | [3.03](/filings/0001104659-26-099752.md) | [1.18](/filings/0001104659-26-120281.md) | [2.22](/filings/0001104659-26-099752.md) | [2.33](/filings/0001104659-26-099752.md) | [3.27](/filings/0001104659-26-099752.md) | [1.51](/filings/0001104659-26-120281.md) |
| Basic EPS | $ per share | [2.15](/filings/0001410578-25-001887.md) | [2.00](/filings/0001410578-25-001887.md) | [2.62](/filings/0001410578-25-001887.md) | [1.07](/filings/0001104659-26-099752.md) | [2.26](/filings/0001104659-26-099752.md) | [2.45](/filings/0001104659-26-099752.md) | [3.14](/filings/0001104659-26-099752.md) | [1.22](/filings/0001104659-26-120281.md) | [2.31](/filings/0001104659-26-099752.md) | [2.44](/filings/0001104659-26-099752.md) | [3.40](/filings/0001104659-26-099752.md) | [1.55](/filings/0001104659-26-120281.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [127](/filings/0001104659-24-007226.md) | [101](/filings/0001410578-24-000570.md) | [95.4](/filings/0001410578-25-001887.md) | [85.1](/filings/0001410578-24-001699.md) | [102](/filings/0001410578-25-000048.md) | [95.8](/filings/0001410578-25-001066.md) | [106](/filings/0001104659-26-099752.md) | [124](/filings/0001104659-25-104478.md) | [337](/filings/0001104659-26-008109.md) | [345](/filings/0001104659-26-055014.md) | [360](/filings/0001104659-26-120281.md) | [236](/filings/0001104659-26-120281.md) |
| Current assets | $m | [1,003](/filings/0001104659-24-007226.md) | [1,119](/filings/0001410578-24-000570.md) | [1,216](/filings/0001410578-25-001887.md) | [1,310](/filings/0001410578-24-001699.md) | [1,325](/filings/0001410578-25-000048.md) | [1,273](/filings/0001410578-25-001066.md) | [1,423](/filings/0001104659-26-099752.md) | [1,477](/filings/0001104659-25-104478.md) | [1,687](/filings/0001104659-26-008109.md) | [1,717](/filings/0001104659-26-055014.md) | [1,612](/filings/0001104659-26-120281.md) | [1,587](/filings/0001104659-26-120281.md) |
| Total assets | $m | [1,726](/filings/0001104659-24-007226.md) | [1,831](/filings/0001410578-24-000570.md) | [1,936](/filings/0001104659-26-099752.md) | [2,114](/filings/0001410578-24-001699.md) | [2,131](/filings/0001410578-25-000048.md) | [2,081](/filings/0001410578-25-001066.md) | [2,241](/filings/0001104659-26-099752.md) | [2,299](/filings/0001104659-26-120281.md) | [2,522](/filings/0001104659-26-008109.md) | [2,554](/filings/0001104659-26-055014.md) | [2,502](/filings/0001104659-26-120281.md) | [2,489](/filings/0001104659-26-120281.md) |
| Current liabilities | $m | [700](/filings/0001104659-24-007226.md) | [762](/filings/0001410578-24-000570.md) | [815](/filings/0001410578-25-001887.md) | [713](/filings/0001410578-24-001699.md) | [704](/filings/0001410578-25-000048.md) | [604](/filings/0001410578-25-001066.md) | [697](/filings/0001104659-26-099752.md) | [792](/filings/0001104659-25-104478.md) | [535](/filings/0001104659-26-008109.md) | [529](/filings/0001104659-26-055014.md) | [511](/filings/0001104659-26-120281.md) | [549](/filings/0001104659-26-120281.md) |
| Total liabilities | $m | [956](/filings/0001104659-24-007226.md) | [1,018](/filings/0001410578-24-000570.md) | [1,073](/filings/0001410578-25-001887.md) | [1,327](/filings/0001410578-24-001699.md) | [1,305](/filings/0001410578-25-000048.md) | [1,202](/filings/0001410578-25-001066.md) | [1,290](/filings/0001104659-26-099752.md) | [1,353](/filings/0001104659-25-104478.md) | [1,677](/filings/0001104659-26-008109.md) | [1,660](/filings/0001104659-26-055014.md) | [1,669](/filings/0001104659-26-120281.md) | [1,707](/filings/0001104659-26-120281.md) |
| Long-term debt | $m | [133](/filings/0001104659-24-007226.md) | [131](/filings/0001410578-24-000570.md) | [129](/filings/0001410578-25-001887.md) | [468](/filings/0001410578-24-001699.md) | [467](/filings/0001410578-25-000048.md) | [465](/filings/0001410578-25-001066.md) | [464](/filings/0001104659-26-099752.md) | [437](/filings/0001104659-25-104478.md) | [999](/filings/0001104659-26-008109.md) | [999](/filings/0001104659-26-055014.md) | [999](/filings/0001104659-26-120281.md) | [998](/filings/0001104659-26-120281.md) |
| Current portion of debt | $m | [8.1](/filings/0001104659-24-007226.md) | [8.2](/filings/0001410578-24-000570.md) | [8.2](/filings/0001410578-25-001887.md) | [8.2](/filings/0001410578-24-001699.md) | [8.2](/filings/0001410578-25-000048.md) | [8.1](/filings/0001410578-25-001066.md) | [8.1](/filings/0001104659-26-099752.md) | [5.4](/filings/0001104659-25-104478.md) | [5.1](/filings/0001104659-26-008109.md) | [3.8](/filings/0001104659-26-055014.md) | [2.5](/filings/0001104659-26-120281.md) | [1.3](/filings/0001104659-26-120281.md) |
| Shareholders' equity | $m | [770](/filings/0001410578-25-001066.md) | [813](/filings/0001410578-25-001066.md) | [863](/filings/0001104659-26-099752.md) | [786](/filings/0001104659-26-008109.md) | [826](/filings/0001104659-26-055014.md) | [879](/filings/0001104659-26-055014.md) | [951](/filings/0001104659-26-120281.md) | [946](/filings/0001104659-26-120281.md) | [845](/filings/0001104659-26-055014.md) | [894](/filings/0001104659-26-055014.md) | [833](/filings/0001104659-26-120281.md) | [783](/filings/0001104659-26-120281.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.5) d](/filings/0001410578-25-000048.md) | [(52.1) d](/filings/0001410578-25-001066.md) | [(29.0) d](/filings/0001104659-26-099752.md) | [(37.2)](/filings/0001104659-25-104478.md) | [52.5 d](/filings/0001104659-26-008109.md) | [81.6 d](/filings/0001104659-26-055014.md) | [0.6 d](/filings/0001104659-26-099752.md) | [17.1](/filings/0001104659-26-120281.md) | [62.2 d](/filings/0001104659-26-008109.md) | [14.5 d](/filings/0001104659-26-055014.md) | [182 d](/filings/0001104659-26-099752.md) | [37.1](/filings/0001104659-26-120281.md) |
| Capital expenditure | $m | [3.5 d](/filings/0001410578-25-000048.md) | [4.9 d](/filings/0001410578-25-001066.md) | [8.5 d](/filings/0001104659-26-099752.md) | [7.7](/filings/0001104659-25-104478.md) | [5.5 d](/filings/0001104659-26-008109.md) | [4.5 d](/filings/0001104659-26-055014.md) | [6.1 d](/filings/0001104659-26-099752.md) | [7.0](/filings/0001104659-26-120281.md) | [6.7 d](/filings/0001104659-26-008109.md) | [7.6 d](/filings/0001104659-26-055014.md) | [9.3 d](/filings/0001104659-26-099752.md) | [7.7](/filings/0001104659-26-120281.md) |
| Share repurchases | $m | not reported | not reported | not reported | [80.4](/filings/0001104659-25-104478.md) | [0.0 d](/filings/0001104659-26-008109.md) | [0.0 d](/filings/0001104659-26-055014.md) | [0.0 d](/filings/0001104659-26-099752.md) | not reported | not reported | [0.0 d](/filings/0001104659-26-055014.md) | [125 d](/filings/0001104659-26-099752.md) | [62.8](/filings/0001104659-26-120281.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.1](/filings/0001104659-24-007226.md) | [17.2](/filings/0001410578-24-000570.md) | [17.2](/filings/0001410578-24-001699.md) | [17.3](/filings/0001410578-25-000048.md) | [17.4](/filings/0001410578-25-001066.md) | [17.1](/filings/0001104659-25-104478.md) | [17.0](/filings/0001104659-26-008109.md) | [17.2](/filings/0001104659-26-055014.md) | [17.5](/filings/0001104659-26-120281.md) | [17.5](/filings/0001104659-26-008109.md) | [17.3](/filings/0001104659-26-055014.md) | [16.3](/filings/0001104659-26-120281.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,728,156 at 2026-10-23, from the cover of the [10-Q filed 2026-10-29](/filings/0001104659-26-120281.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 20:27 ET. No prices; not investment advice.